Elios' Phase IIb Melanoma Data Are Promising, But Present Tricky Issues For Phase III Vaccine Study
The biotech’s personalized vaccine shows it can reduce the risk of melanoma recurrence by 50% in the per-treatment population, but Phase III will need to demonstrate a similar benefit in an intent-to-treat population.
You may also be interested in...
Now that it is clear the immune system can kill cancer, all kinds of companies are obsessed with the idea. Start-ups are tailoring business models to divergent technologies and market dynamics.
Oral or feeding tube administration of the cerebral neuroprotectant should offer flexible dosing options for amyotrophic lateral sclerosis patients, the firm says.
The Danish diabetes titan teams with Moderna’s founder on cardiometabolic R&D. Troubled cell therapy biotech Bone Therapeutics negotiates reverse merger with Medsenic.